Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS)
Health Care · Biotechnology · US
$2.02
-5.61% today · -4.7% 1Y
Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $146.08M and employs 61 people.
Over the last twelve months the share price has lost 4.7%, trading between 1.50 and 3.60.
Tweenvest scores Acumen Pharmaceuticals, Inc. across four factors: quality 51/100, value 67/100. Its strongest factor is value.
ABOS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $146.08M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.64
- Dividend yield
- —
- Beta (5Y)
- 0.33
- 52-week high
- $3.60
- 52-week low
- $1.50
- Avg volume (3M)
- —
- Shares outstanding
- 72.32M
- Employees
- 61
- Next earnings
- —
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
- ISIN
- US00509G2093
- Founded
- 1996
- Listed since
- Jul 1, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Scancell Holdings plcAIM: SCLP | $149.18M | £0.09 | +0.54% |
| Molecular Partners AGSWX: MOLN | $148.00M | CHF3.21 | -3.60% |
| Actinogen Medical LimitedASX: ACW | $147.68M | AU$0.06 | +1.85% |
| JW (Cayman) Therapeutics Co. LtdSEHK: 2126 | $146.12M | HK$2.83 | +5.21% |
| CANbridge Pharmaceuticals Inc.SEHK: 1228 | $145.79M | HK$1.92 | -6.59% |
| Kangstem Biotech Co., Ltd.KOSDAQ: A217730 | $144.47M | ₩2,065.00 | -7.81% |
| Atrium Therapeutics, Inc.NasdaqGS: RNA | $143.69M | $8.21 | -2.26% |
| UnicoCell Biomed Co., Ltd.TWSE: 6794 | $142.50M | NT$71.60 | -9.25% |
Figures last refreshed Oct 11, 2026.